NCT00423137

Effect of BIBW 2948 BS in COPD

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of a 4-week Treatment of 15 and 30 mg b.i.d BIBW2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) on Epithelial Mucin Stores and the Safety and Efficacy in COPD Patients With Symptoms Associated With Chronic Bronchitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Study of BIBW 2948 BS in Patients with COPD and Chronic Bronchitis

Conditions

• Pulmonary Disease, Chronic Obstructive
• Bronchitis, Chronic

Interventions

Type	Name	Description
DRUG	BIBW 2948 BS	Capsule
DRUG	Placebo	Capsule

Timeline

• Start date: 2007-01-17
• Primary completion: 2008-07-09
• Completion: 2008-07-09
• First posted: 2007-01-18
• Last updated: 2021-11-19
• Results posted: 2021-11-19

Locations

6 sites across 2 countries: United States, Germany